StockNews.com Downgrades XOMA (NASDAQ:XOMA) to Sell

XOMA (NASDAQ:XOMA) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $123.00 target price on shares of XOMA in a research report on Tuesday.

XOMA Trading Down 2.3 %

NASDAQ XOMA opened at $25.67 on Wednesday. The stock has a 50-day moving average of $29.28 and a 200-day moving average of $27.95. XOMA has a 1-year low of $18.57 and a 1-year high of $35.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a market cap of $302.47 million, a PE ratio of -7.38 and a beta of 0.92.

Insider Buying and Selling at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the transaction, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares during the last quarter. Geode Capital Management LLC boosted its position in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 1,138 shares during the last quarter. Rhumbline Advisers grew its stake in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the period. State Street Corp increased its position in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.